Introduction {#S0001}
============

The genus of *Aeromonas* spp., an emerging cluster of opportunistic pathogens, is frequently implicated in a number of human intestinal and extra-intestinal infections.[@CIT0001]--[@CIT0005] Since a majority of intestinal infections caused by *Aeromonas* spp. are self-limiting, Clinical and Laboratory Standard Institution (CLSI) recommends that antimicrobial susceptibility testing is usually applicable to extra-intestinal isolates. 3rd and 4th generation cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole are recommended for primary testing.[@CIT0006] However, the abuse of antimicrobial agents, the expression and transmission of mobile resistant elements accelerate the evolution of these opportunistic pathogens in antimicrobial resistance.[@CIT0007],[@CIT0008]

In contrast to previous studies of *Aeromonas* infections in other regions,[@CIT0004],[@CIT0009]--[@CIT0011] Asia harbored a relatively high proportion of resistant isolates to ciprofloxacin and ceftriaxone. Southern India found a high resistance rate of 31.0% to ceftriaxone in intestinal strains.[@CIT0012] Korea and Southern Taiwan reported resistance rates of 5%−15% to ciprofloxacin and ceftriaxone in bloodstream strains,[@CIT0013],[@CIT0014] while a very recent study from Northern China further illustrated that resistance rates of extra-intestinal isolates to ciprofloxacin and ceftriaxone were 35.3% and 70.6%,[@CIT0015] respectively. However, a dearth of data was regarding this problem in Southwest China. Moreover, aforementioned studies failed to correlate AMR patterns with possible sources of infections and the heterogeneity of AMR profiling of *Aeromonas* spp. in distinct infections was unknown.

More importantly, since the interpretive criteria for cefepime, imipenem and meropenem to *Aeromonas* had been refined by CLSI M45-A3 in 2015[@CIT0006] and the epidemiology and AMR patterns of clinically important *Aeromonas* isolates varies greatly over time by region; therefore, it is necessary to revisit their antibiograms to present concurrent microbial evidence for clinical decision-making and to reflect on the local situation, compared to international data.[@CIT0016],[@CIT0017] However, data concerning about the alteration of antibiogram in clinical *Aeromonas* species are lacking in mainland China.

To fill this gap, we launched a seven-year retrospective multicenter study from 2011 to 2017 to elucidate the distributions and antibiogram of clinically important *Aeromonas* species in Chongqing, Southwest China. AMR patterns were further compared by sources and species. Temporal alterations of AMR profiling were then analyzed between the two periods of 2011--2014 and 2015--2017.

Methods {#S0002}
=======

Study Design And Data Enrollment Criteria {#S0002-S2001}
-----------------------------------------

This retrospective study was carried out in the first affiliated hospital of Chongqing Medical University from 2011 to 2017, which was a branch of China Antimicrobial Resistance Surveillance System (CARSS) in Southwest China. All data were collected from the database of CARSS. Only the first isolate characterized with all the following information (patients' age, unique patient identification number, specimen type and antibiotic susceptibility with minimal inhibitory concentration (MIC) values) was included and a given *Aeromonas* species with a total number of less than 30 was exempt from AMR pattern analysis according to the recommendation of CLSI M39-A4.[@CIT0018]

Bacteria Identification And Antimicrobial Susceptibility {#S0002-S2002}
--------------------------------------------------------

All participated laboratories conformed to standard procedures to perform identification and antimicrobial susceptibility testing by semi or automated microbial system. MICs were interpreted by CLSI M45-A3.[@CIT0006]

Definition {#S0002-S2003}
----------

Clinically important *Aeromonas* species included *Aeromonas hydrophila* complex (*A. hydrophila* complex), *Aeromonas veronii* complex (*A. veronii* complex) and *Aeromonas caviae* complex (*A. caviae* complex) on the recommendation of CLSI M45-A3.[@CIT0006]

*Aeromonas veronii* complex was a cluster of pathogens including *Aeromonas veronii, Aeromonas sobria, Aeromonas veronii biovar sobria* and *Aeromonas veronii biovar veronii*.[@CIT0019]

Strains isolated from stool specimens were defined as intestinal strains, while those isolated from other specimens were defined as extra-intestinal strains.

Statistical Analysis {#S0002-S2004}
--------------------

Raw data were processed by Whonet 5.6 software and then statistically analyzed on Graphpad prism 6 software. Chi-square test or Fisher's exact test was adopted to examine distribution and changes in AMR patterns. Statistical significance was determined if a two-tailed *p* value was no more than 0.05.

Results {#S0003}
=======

The Distribution Of Clinical *Aeromonas* Isolates {#S0003-S2001}
-------------------------------------------------

During this seven-year study period, a total of 1461 strains was isolated and 1135 strains were included according to the inclusion criteria. *A. hydrophila* complex (65.6%, 745/1135) was the most predominant species, followed by *A. veronii* complex (16.7%, 190/1135) and *A. caviae* complex (15.3%, 174/1135). Interestingly, 21 strains of *Aeromonas salmonicida* (*A. salmonicida*) and 5 strains of *Aeromonas schubertii* (*A. schubertii*) were firstly reported in our branch ([Table 1](#T0001){ref-type="table"}). The most common specimen source of species was sputum (27.7%, 314/1135), followed by wound (20.8%, 236/1135), bloodstream (10.8%, 123/1135) and urine (8.8%, 100/1135). Intestinal samples contribute to 4.3% (49/1135) of all strains. Significant different distribution of species was observed between nine distinct sources (*p* = 0.0002).Table 1The Sources And Species Distribution Of Clinical *Aeromonas* StrainsSources*Aeromonas HydrophilaAeromonas VeroniiAeromonas CaviaeAeromonas SalmonicidaAeromonas Schubertii*Total(745)\*(190)(174)(21)(5)(1135)Sputum185 (24.8%)^\#^31 (16.3%)79 (45.4%)14 (66.7%)5 (100%)314 (27.7%)Urine61 (8.2%)14 (7.4%)24 (13.8%)1 (4.8%)100 (8.8%)Wound secretion181 (24.3%)28 (14.7%)26 (14.9%)1 (4.8%)236 (20.8%)Blood70 (9.4%)40 (21.1%)13 (7.5%)123 (10.8%)Bile51 (6.8%)11 (5.8%)10 (5.7%)72 (6.3%)Stool33 (4.4%)12 (6.3%)4 (2.3%)49 (4.3%)Abscess61 (8.2%)19 (10%)6 (3.4%)3 (14.3%)89 (7.8%)Ascites11 (1.5%)13 (6.8%)2 (1.1%)26 (2.3%)[^1]

The Antibiogram Of Clinical *Aeromonas* Isolates By Specimen Sources {#S0003-S2002}
--------------------------------------------------------------------

AMR patterns of clinical *Aeromonas* isolates from the top six specimen sources were illustrated in [Figure 1A](#F0001){ref-type="fig"}. Briefly, all isolates demonstrated high resistance to trimethoprim-sulfamethoxazole, with resistance rates ranged from 22.2% to 56.6%, while those to piperacillin/tazobactam, imipenem and meropenem were less than 10%. Interestingly, in comparison to intestinal isolates, urinary isolates exhibited significantly high resistance rates to ceftriaxone (65.6%, *X*^2^ = 11.45, df = 1, *p* = 0.001), ceftazidime (52.1%, *X*^2^ = 6.651, df = 1, *p* = 0.001), aztreonam (44.3%, *X*^2^ = 6.247, df = 1, *p* = 0.012), ciprofloxacin (47.7%, *X*^2^ = 5.017, df = 1, *p* = 0.025), levofloxacin (35.9%, *X*^2^ = 7.537, df = 1, *p* = 0.006), gentamicin (24.7%, *X*^2^ = 6.299, df = 1, *p* = 0.012) and trimethoprim-sulfamethoxazole (56.6%, *X*^2^ = 4.409, df = 1, *p* = 0.035), respectively.Figure 1AMR patterns of clinically important *Aeromonas* isolates by sources and species. (**A**) AMR profiling of clinical *Aeromonas* isolates from top six specimen sources. (**B**) AMR profiling of three clinically important *Aeromonas* species. *A. hydrophila: Aeromonas hydrophila* complex; *A. veronii: Aeromonas veronii* complex; *A. caviae: Aeromonas caviae* complex. Asterisks indicate statistical significance as *p* values were less than 0.05.**Abbreviations:** TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MEM, meropenem; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole.

As observed in urinary strains, intestinal strains found their resistance rates to most of the studied antimicrobials exceeded 20%, except to imipenem, gentamicin and levofloxacin (6.7%, 2.3% and 13.3%, respectively). None of them was resistant to meropenem. Of note, biliary strains presented different AMR profiling and showed high resistance rates particularly to ceftriaxone (42.1%) and ceftazidime (25.4%). It seemed that biliary strains were more resistant to ceftriaxone than intestinal strains, while the difference was not statistically significant (*X*^2^ = 1.47, df = 1, *p =* 0.225). Unlike those from the aforementioned sources, respiratory, bloodstream and skin strains shared similar AMR patterns and illustrated resistance rates of less than 20% to all tested antimicrobials but trimethoprim-sulfamethoxazole. Notably, bloodstream contributed to most of meropenem-resistant strains with a percentage of 14.3% in comparison to other sources (*X*^2^ = 17.05, df = 5, *p =* 0.0009).

The Antibiogram Of Clinical *Aeromonas* Isolates By Species {#S0003-S2003}
-----------------------------------------------------------

In terms of *A. hydrophila* complex, 30.2% of them was resistant to ceftriaxone. Resistance rates to ceftazidime, cefepime, aztreonam and ciprofloxacin were near to 20%, while those to piperacillin/tazobactam, imipenem, and meropenem were less than 10%. In contrast to *A. hydrophila* complex, *A. caviae* complex exhibited notably high resistance rate to ceftazidime (25.9%) and cefepime (19.0%), but low resistance to imipenem (1.8%) and meropenem (1.6%). However, *A. veronii* complex witnessed a resistance rate of less than 10% to a majority of tested antibiotics and exhibited significantly low resistance rates to ceftriaxone, ceftazidime, cefepime, aztreonam and ciprofloxacin in comparison to *A. hydrophila* complex ([Figure 1B](#F0001){ref-type="fig"}).

Trends Of Antimicrobial Resistance In Extra-Intestinal Isolates From 2012 to 2017 {#S0003-S2004}
---------------------------------------------------------------------------------

Since AMR patterns of these three predominant species were distinct, we further analyzed changes of their antibiogram after the implementation of CLSI-M45-A3 (2015). Between 2011--2014 and 2015--2017, resistance rates of *A. hydrophila* complex to all the tested antibiotics remained stable and similar tendency was found in *A. caviae* complex ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). Interestingly, *A. veronii* complex showed a decreasing trend of resistance to a majority of these tested antibiotics and a significant declination to ceftazidime from 19.4% to 6.8% during the same timeframe (*X*^2^ = 6.02, df = 1, *p =* 0.01, [Figure 2C](#F0002){ref-type="fig"}).Figure 2Shifting trend in antibiogram of clinically important *Aeromonas* species from 2011--2014 to 2015--2017. (**A**) *A. hydrophila: Aeromonas hydrophila* complex; (**B**) *A. caviae: Aeromonas caviae* complex; (**C**) *A. veronii: Aeromonas veronii* complex. Asterisks indicate statistical significance as *p*values were less than 0.05.**Abbreviations:** TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MEM, meropenem; GEN, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole.

Discussion {#S0004}
==========

This study presented the current available evidence of distributions and AMR patterns of clinical *Aeromonas* species and illustrated the heterogeneity and evolution of these species in Southwest China. Although sputum was the most common source of clinical *Aeromonas* species, it is arbitrary to deduce that respiratory tract infection dominates clinical *Aeromonas* infections during this seven-year investigation period. A nationwide study from France reported that respiratory tract infection contributed to only 6% of the *Aeromonas* infections.[@CIT0020] Furthermore, clinical study in Taiwan only found 8 pneumonia (9.4%) out of 85 patients with *Aeromonas* species isolated from respiratory tracts.[@CIT0021] Added that pneumonia tended to be related to aspiration of vomitus in patients with *Aeromonas* colonizing their gut,[@CIT0022] it is speculated that our high isolating rate may be overestimated by the potential transient colonization of *Aeromonas* species in patient's respiratory tract and cross-infections during hospitalization.

Of interest, in this present study, high resistance of urinary strains to primary testing agents (3rd and 4th generation cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole recommended by CLSI) was previously unreported in China. This exclusive AMR phenotype resembled that of multidrug-resistant *Escherichia coli* strains, which we have previously verified co-carried plasmid-encoded extended-spectrum beta-lactamases (ESBLs) genes, aminoglycosides resistance determinants (ARDs) and fluoroquinolones resistance determinants (QRDs).[@CIT0023] Further findings from South India have proved that the *bla*~CTX-M~ gene originated from ceftriaxone-resistant *Aeromonas* species were transmissible to recipient (*Escherichia coli* J53 strain) and resulted in the emergence of ceftriaxone resistant phenotypes.[@CIT0012] Moreover, a recent surveillance study focusing on antibiotic sales of 468 China's tertiary hospitals from 28 provinces illustrated the preference consumption of cephalosporins and fluoroquinolones.[@CIT0024] More importantly, the consumption of 3rd and 4th generation cephalosporins, as well as fluoroquinolones in China during 2011 and 2015 was higher per capita consumption percentage than that in at least 75% of the 29 European countries.[@CIT0024] This high consumption may accelerate the transmission of mobile resistant elements. Accordingly, it is deduced the high antibiotic selective pressure and the potential transmission of plasmid-encoded ESBLs genes, aminoglycosides and fluoroquinolones resistance determinants between species may contribute to our AMR phenotype.

To date, data of *Aeromonas* bacteremia in mainland China are lacking, while this present study illustrated *A. hydrophila* complex was predominant in *Aeromonas* bacteremia. This is consistent with the results of studies in Korean peninsula and Ethiopia[@CIT0013],[@CIT0025] but contrasts with a 16-year retrospective study in Japan with the predominance of *A. caviae*.[@CIT0026] Since most of *Aeromonas* bacteremia were secondary to hepatobiliary tract infections and peritonitis and our present data showed *A. hydrophila* complex was predominant in bile and ascites, it is supposed that the heterogeneity of primary infections and immune state of patients should be blamed for this discrepancy in *Aeromonas* bacteremia. Consistent with the aforementioned studies, less than 20% of the bloodstream isolates were resistant to any of the antibiotics tested. However, it was noteworthy that carbapenem resistance presented in 9.6% to 14.3% of the bloodstream isolates. Although Metallo-beta-lactamase CphA has been well recognized to confer carbapenem resistance of *Aeromonas*, recent studies have alarmed that plasmid-borne *bla*~KPC-2~, *bla*~OXA-181,~ *bla*~VIM-1~ and *bla*~VIM-35~ genes contribute to carbapenem resistance of clinical *Aeromonas* species worldwide.[@CIT0027]--[@CIT0030] Therefore, the evolution and transmission of carbapenemase genes in clinical *Aeromonas* species deserved more attention in our branch.

More importantly, our intestinal isolates demonstrated the highest resistance rates of approximately 30% to ceftriaxone, ceftazidime, ciprofloxacin and trimethoprim-sulfamethoxazole in mainland China, hinting the potential clinical empirical therapeutic failure of *Aeromonas* associated diarrhea and necessitates primary antimicrobial susceptibility testing of other antibiotics among intestinal isolates in our branch. Moreover, in consistent with the results in Tehran[@CIT0031] but on the contrary to two recent studies in mainland China,[@CIT0015],[@CIT0032] intestinal isolates with high resistance to ciprofloxacin was predominant and may be ascribed to the transmission of plasmid-mediated quinolone resistance genes, since *qnrS2* gene was found ubiquitous in aquatic environments near Chinese hospitals and *Aeromonas* spp. might serve as vectors for qnrS2 with the help of IncQ-type plasmids.[@CIT0033] Luckily, gentamicin and carbapenems were still effective to fight against intestinal isolates, less than 7% were resistant to them. Moreover, since resistance rates of isolates from bloodstream, bile and wound were less than 10%, empirical adoption of piperacillin/tazobactam, cefepime, imipenem, gentamicin and levofloxacin may be still effective to fight against these *Aeromonas* infections. In contrast, only piperacillin/tazobactam, imipenem and meropenem may be still active to fight against urinary infection by *Aeromonas* spp, less than 7% were resistant to them.

Interestingly, 21 strains of *A. salmonicida* were firstly reported in our branch. To the best of our knowledge, no systemic reports were regarding the isolation of *A. salmonicida* from clinical samples in China. Previous case reports have linked *A. salmonicida* to postoperative endophthalmitis, bacteremia and diarrhea.[@CIT0032],[@CIT0034],[@CIT0035] Instead, this present study uncovered that *A. salmonicida* was frequently isolated from sputum, hinting it as a potential causative pathogen to nosocomial pneumonia. Moreover, Vincent AT et al have recently confirmed the pathogenicity and virulence of clinical *A. salmonicida* isolates in a mouse model and suggested the inclusion of *A. salmonicida* in clinical diagnosis.[@CIT0036]

Distinct AMR patterns were found between these three predominant species. *A. caviae* complex harbored higher resistance to ceftazidime and cefepime than *A. hydrophila* complex. Moreover, the phenotype of high resistance to 3rd or 4th generation cephalosporins but low resistance to carbapenems suggested the presence of preponderant mobile resistance elements in *A. caviae* complex. Case report of *A. caviae* pneumonia in China firstly uncovered the co-carrier of CTX-M-3, TEM-1 and a new plasmid-mediated MOX-4 AmpC-encoding gene conferred resistance to third or fourth generation cephalosporins but not to carbapenems.[@CIT0037] It is deduced that the emergence and transmission of novel ESBLs and AmpC genes may be blamed for this phenotype. Despite that Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region demonstrated the increasing resistance rate of intro-abdominal *Aeromonas* isolates to ciprofloxacin from 2003 to 2010,[@CIT0038] we did not find statistically significant alteration in the antibiogram of these three predominant species during the timeframe of 2011--2014 and 2015--2017, thus the impact of the revision of breakpoints on antibiogram was insignificant in our setting.

Several limitations should not be neglected in this present study. First, this study was not aimed to study the taxonomy of *Aeromonas* spp., so the verification of taxonomic affiliation was not fulfilled. Definitely, *A. dhakensis*, an increasingly recognized human pathogen, previously under the umbrella of *A. hydrophila*,[@CIT0002] has been isolated from clinical samples in China; however, a total of four clinical isolates underdetermined clinical significance of this species in domestic hospitals.[@CIT0015] Second, due to the inaccessibility of clinical data by CARSS, this study failed to discuss the association of patients' clinical characteristics with *Aeromonas* infections, while previous studies have verified that the most common medical conditions among patients with *Aeromonas* infections were malignancy and liver-transplant related cholecystitis.[@CIT0015] Third, since the strains were not collected from the participated laboratories, this study failed to investigate virulence and resistance mechanisms of *Aeromonas* isolates.

Conclusions {#S0005}
===========

Distinct distribution and AMR patterns of clinical *Aeromonas* species in Southwest China highlighted the predominance of *A. hydrophila* complex and high resistance rates of urine and intestinal isolates against 3rd and 4th generation cephalosporins and ciprofloxacin. Piperacillin/tazobactam and carbapenems are active against these urinary isolates. Routine-use antibiotics may be efficient to fight against *Aeromonas* bacteremia, while high resistance rate to meropenem may hinder its clinical efficacies. Temporally constant AMR patterns should not unbrace antimicrobial stewardships of *Aeromonas* infections. The potential role of *Aeromonas* spp. in nosocomial pneumonia deserves more researches and additional studies are needed.
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[^1]: **Abbreviations:** (X)\*, X is the total number of strains; Y(Z)^\#^, Z is the proportion of Y in the total strains (Z=Y/X×100%).
